Nearly one in three people with generalized myasthenia gravis (gMG) experienced prolonged periods of few or no symptoms while on treatment with Imaavy (nipocalimab-aahu), according to more than two years of data from a global clinical trial. These and other data from the…
News
An investigational autoinjector device for administering Zilbrysq (zilucoplan), an approved therapy for generalized myasthenia gravis (gMG), is a safe and effective option for individuals now using the currently available prefilled syringe, according to new data from two clinical trials. Users were “highly satisfied” with the Zilbrysq autoinjector and…
Cemdisiran, an experimental therapy given by injection under the skin every three months, was shown to significantly and sustainably ease symptoms of generalized myasthenia gravis (gMG) in a global, late-stage clinical trial called NIMBLE. In addition to suggesting that cemdisiran is an effective gMG treatment, the trial results…
Kyverna Therapeutics’ experimental cell therapy KYV-101, now called mivocabtagene autoleucel (miv-cel), was associated with rapid, sustained symptom improvements in all seven participants with hard-to-treat generalized myasthenia gravis (gMG) in a clinical trial. The data specifically show that all seven treated to date with miv-cel in the Phase…
A new U.S.-based patient registry is enrolling people with myasthenia gravis (MG) to help researchers better understand how the disease progresses, how treatments are used in the real world, and how MG affects patients’ daily lives. Launched by Alira Health in partnership with the Autoimmune Neurology Alliance, the…
Myasthenia gravis (MG) patients who lack the three most common disease-causing antibodies often respond poorly to standard immunosuppressive medications, with many — especially those with hard-to-treat disease — failing to see their symptoms fully controlled. That’s according to a single-center study in Greece that also showed that only about…
Physical activity and respiratory (breathing) muscle training may help people with myasthenia gravis (MG) reduce symptoms and improve daily functioning, especially when programs are adapted to their needs, according to a review study. “Individualized exercise programs are essential to ensure safety and optimize adherence,” the researchers wrote.
Zilbrysq (zilucoplan) helped ease disease symptoms and improve quality of life for most people with generalized myasthenia gravis (gMG) in an expanded access program (EAP) in France, a study showed. EAPs provide access to experimental therapies, or those already approved but not yet on the market, outside clinical…
Vyvgart (efgartigimod alfa-fcab) may be a safe and effective treatment for children and adolescents with juvenile myasthenia gravis (JMG), according to new real-world data from China. The study found that the therapy, developed by Argenx and currently approved for certain adults with…
Most children with juvenile myasthenia gravis (JMG) develop mild disease marked by eye muscle weakness, with more severe symptoms seen in those who are older when they start showing signs of disease, according to a single-center study in China. Data also suggested that blood levels of self-reactive antibodies against anti-acetylcholine…
Recent Posts
- Trial data show long-term promise for gMG treatment Imaavy
- The weight of being an MG advocate: Why rest is as vital as your voice
- Zilbrysq autoinjector found safe, effective in trials for use in gMG
- Dieting to be in better shape, not to have a perfect shape
- Mental health challenges are often an invisible aspect of MG